External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival

References

• Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology Am Soc Hematol Educ Program. 2016;1:366–378.
   Google Scholar
• International Non-Hodgkin‘s Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin‘s lymphoma. N Engl J Med. 1993;329(14):987–994.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–1861.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–842.
   PubMed Web of Science ®Google Scholar
• Moons KG, Altman DG, Reitsma JB, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1–73.
   PubMed Web of Science ®Google Scholar
• Steyerberg EW. Evaluation of performance. In: Clinical prediction models a practical approach to development, validation, and updating. Springer; 2019. p. 277–308.
   Google Scholar
• Song JL, Wei XL, Zhang YK, et al. [The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2018;39(9):739–744.
   PubMedGoogle Scholar
• Biccler J, Eloranta S, de Nully Brown P, et al. Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI. Cancer Med. 2018;7(1):114–122.
   PubMed Web of Science ®Google Scholar
• Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041–2048.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Habermann TM, Shi Q, et al. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol. 2018;29(8):1822–1827.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842–858.
   PubMed Web of Science ®Google Scholar
• Zhu J, Yang Y, Tao J, et al. Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review. Leukemia. 2020;34(10):2576–2591.
   PubMed Web of Science ®Google Scholar
• Stein HCJK, Warnke RA, Gatter KC, et al. Diffuse large B-cell lymphoma, NOS. In: Swerdlow SHCE, Harris NL, Jaffe ES, Pilari SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of hematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 233–238.
   Google Scholar
• Gascoyne RDCJKC, Campo E, Rosenwald A, et al. Diffuse large B-cell lymphoma, NOS. In: Swerdlow SHCE, Harris NL, Jaffe ES, Pilari SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R, editors. WHO classification of tumours of hematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 291–297.
   Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
   PubMed Web of Science ®Google Scholar
• Chotipanich CPC, Kunawudhi A, Theerakulpisut D. Appropriate use of F18-FDG PET/CT in oncology, cardiology, and neurology in Thailand: report and recommendations from the health intervention and technology assessment program. J Med Assoc Thai. 2019;102(7):820–839.
   Google Scholar
• Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. Stat Med. 2016;35(2):214–226.
   PubMed Web of Science ®Google Scholar
• Harrell FE J, Califf R, Pryor D, et al. Evaluating the yield of medical tests. JAMA. 1982;247(18):2543–2546.
   PubMed Web of Science ®Google Scholar
• Newson RB. Comparing the predictive powers of survival models using Harrell‘s C or Somers’ D. Stata J. 2010;10(3):339–358.
   Web of Science ®Google Scholar
• Klapper W, Kreuz M, Kohler CW, et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood. 2012;119(8):1882–1887.
   PubMed Web of Science ®Google Scholar
• Gordon LI, Andersen J, Colgan J, et al. Advanced diffuse non-Hodgkin‘s lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study. Cancer. 1995;75(3):865–873.
   PubMed Web of Science ®Google Scholar
• Montalban C, Diaz-Lopez A, Dlouhy I, et al. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of beta2 -microglobulin yields a more accurate GELTAMO-IPI. Br J Haematol. 2017;176(6):918–928.
   PubMed Web of Science ®Google Scholar
• Gao R, Liang JH, Wang L, et al. Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma. Int J Cancer. 2018;143(8):1884–1895.
   PubMed Web of Science ®Google Scholar
• Kang J, Yoon S, Suh C. Relevance of prognostic index with beta2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era. Blood Res. 2017;52(4):276–284.
   PubMed Web of Science ®Google Scholar
• Feng YX, Su LP. [Prognostic value of international prognostic index, revised international prognostic index, enhanced international prognostic index and Grupo Espanol de Linfomas/trasplante autologo de medula osea-international prognostic index for diffuse large B-cell lymphoma]. Zhonghua Zhong Liu Za Zhi. 2020;42(11):949–954.
   PubMedGoogle Scholar